Proteins for life

We're Here To Solve Your Biggest Protein Challenges

ExpreS2ion develops a portfolio of vaccines for diseases such as COVID-19, influenza and breast cancer through the use of its non-viral Drosophila S2 cells-based expression system, ExpreS2, that is recognized for handling even the toughest protein challenges.

The company also collaborates on additional projects, including several malaria vaccines, and offers a range of protein expression and production services from discovery to pre-clinical development and cGMP production.

Latest press release

ExpreS2ion - Annual report for 2020 published

Hørsholm, Denmark, May 05, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that the company's annual report for the financial year 2020 is published. The annual report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com).

Read more